(J Diabetes Invest, doi: 10.1111/jdi.12004, 2013)

Introduction {#jdi12004-sec-0005}
============

It is widely accepted that chronic inflammation is profoundly involved in the development of atherosclerosis[1](#jdi12004-bib-0001){ref-type="ref"}. Adhesion molecules, pro‐inflammatory cytokines and chemokines, including soluble intercellular adhesion molecule‐1 (sICAM‐1), interleukin‐18 (IL‐18) and monocyte chemotactic protein‐1 (MCP‐1), are involved in the pathogenesis of diabetic nephropathy as well as atherosclerosis[2](#jdi12004-bib-0002 jdi12004-bib-0003){ref-type="ref"}. C‐reactive protein (CRP) is a good marker for cardiovascular risk[4](#jdi12004-bib-0004){ref-type="ref"}, and is a precipitating factor for diabetic nephropathy[5](#jdi12004-bib-0005){ref-type="ref"}. Angiotensin II, which is produced by the renin--angiotensin system (RAS), is known to promote inflammation[6](#jdi12004-bib-0006){ref-type="ref"}. Inhibition of the RAS and associated inflammation might be renoprotective in chronic renal diseases, including diabetic nephropathy[6](#jdi12004-bib-0006 jdi12004-bib-0007){ref-type="ref"}.

Oxidative stress is a critical pathogenic component of atherosclerosis and diabetic nephropathy[8](#jdi12004-bib-0008){ref-type="ref"}. After the onset of renal disorders, the levels of pro‐inflammatory cytokines and oxidative stress begin to increase, inducing cardiovascular diseases through vascular endothelial dysfunction[9](#jdi12004-bib-0009){ref-type="ref"}. Furthermore, an increase in oxidative stress has been reported in hyperglycemic rats[10](#jdi12004-bib-0010){ref-type="ref"}. While activation of the RAS increases oxidative stress, angiotensin‐converting enzyme inhibitors (ACEI)[11](#jdi12004-bib-0011){ref-type="ref"} and angiotensin II type 1 receptor blockers (ARB)[12](#jdi12004-bib-0012){ref-type="ref"} inhibit oxidative stress.

Combination therapy with an ACEI and an ARB has been considered in several renal diseases to protect the kidney by potently inhibiting RAS activity[13](#jdi12004-bib-0013){ref-type="ref"}. In the context of diabetic nephropathy[6](#jdi12004-bib-0006 jdi12004-bib-0013 jdi12004-bib-0014){ref-type="ref"}, combination therapy was found to reduce albuminuria. However, most of the studies testing ACEI/ARB combination therapy in diabetic nephropathy were short‐term observational studies, and clinical studies attempting to elucidate the mechanisms underlying these renoprotective effects are not sufficient[15](#jdi12004-bib-0015){ref-type="ref"}.

In patients with diabetic nephropathy, ACEI/ARB combination therapy is expected to have more potent anti‐inflammatory and anti‐oxidative stress effects than monotherapy at the systemic and local levels in the kidney. Combination therapy might also inhibit the development or progression of atherosclerosis and diabetic nephropathy more potently than monotherapy. However, to our knowledge, no clinical studies have evaluated the anti‐inflammatory and anti‐oxidative stress effects of combination therapy. Therefore, we carried out a randomized controlled study of ACEI/ARB combination therapy vs ARB monotherapy in patients with type 2 diabetes and early nephropathy to compare the anti‐inflammatory and anti‐oxidative stress effects of these therapies.

Materials and Methods {#jdi12004-sec-0006}
=====================

Study Design {#jdi12004-sec-0007}
------------

Patients meeting the following inclusion criteria were eligible for the present study: age 30--74 years, diagnosed with type 2 diabetes, disease duration ≥7 years, diagnosis of diabetic neuropathy and retinopathy, creatinine clearance (C~Cr~; determined using the Cockcroft--Gault formula) \>60 mL/min and urinary albumin/creatinine ratio (ACR) \>30 mg/gCr. The diagnosis of type 2 diabetes was made according to the World Health Organization criteria.

Patients meeting any of the following criteria were excluded from the present the study: patients with chronic inflammatory disease or malignancies, pregnant women or women who wished to become pregnant, patients with renovascular hypertension, patients with hemoglobin A1C (A1C; National Glycohemoglobin Standardization Program) \>9.4%; patients with blood pressure (BP) \>180/110 mmHg and patients who had participated in another clinical trial within 3 months before enrolling in the present study. At the discretion of the investigator, patients who had previously used an ACEI or ARB that could not be washed out were also excluded. Concomitant use of steroids, potassium‐sparing diuretics, digoxin, or anti‐arrhythmic drugs except for β‐blockers and calcium channel blockers was not allowed. Concomitant use of new statins or thiazolidinedione derivatives was not allowed during the washout or observation periods. Blood glucose levels were to be controlled by adjusting the dose of medications already in use.

Written informed consent was obtained from all participants. The present study was approved by the Ethics Committee of Okayama Saiseikai General Hospital.

The design of the present study is summarized in Figure [1](#jdi12004-fig-0001){ref-type="fig"}a. During the washout period, previous ACEIs or ARBs were discontinued and switched to amlodipine (5 mg/day). The observation period was started 8 weeks after starting treatment with amlodipine. In the present study, we treated patients with losartan (ARB) and imidapril (ACEI) or losartan alone during the observation period. Amlodipine was stopped when starting combination or monotherapy.

![(a) Study design. During the washout period, angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) were discontinued and switched to amlodipine (5 mg/day). At the end of the washout period, patients were allocated to either monotherapy (100 mg/day losartan) or combination therapy (50 mg/day losartan plus 5 mg/day imidapril) and followed for 48 weeks. (b) Patient disposition. Four patients were excluded from this study during the washout period, including one patient who refused to participate in the study, two patients with an ACR \< 30 mg/gCr and one patient with C~Cr~ \< 60 mL/min. Of the 32 patients who started the observation period, 28 were treated for 48 weeks and were included in the analysis.](jdi-4-195-g1){#jdi12004-fig-0001}

For losartan monotherapy, the losartan dose was 100 mg/day. In combination therapy, the doses of losartan and imidapril were 50 and 5 mg/day, respectively. The first patient enrolled in the study was allocated to monotherapy, with subsequent patients allocated to one of the two therapies.

During the observation period, patients were to be discontinued or withdrawn from the study if BP could not be maintained at \<180/110 mmHg, C~Cr~ decreased to 60 mL/min, serum creatinine increased from baseline by ≥30%, or if an adverse drug reaction possibly related to therapy occurred.

Data Collection {#jdi12004-sec-0008}
---------------

After the baseline visit, patients were instructed to visit the hospital at 8, 16, 24 and 48 weeks. At each visit, physical findings, BP, hematological parameters, urinalysis parameters and complications were assessed (Figure [1](#jdi12004-fig-0001){ref-type="fig"}b). Venous blood and urine samples were obtained in the early morning after an overnight fast. BP was measured by the same person in the morning. After a 5‐min rest in a sitting position, BP was measured in triplicate to calculate the mean for assessment.

Analysis of Biomarkers {#jdi12004-sec-0009}
----------------------

The primary objective of the present study was to evaluate the anti‐inflammatory and anti‐oxidative stress effects of imidapril/losartan combination therapy by measuring the serum concentrations of high‐sensitivity CRP (hs‐CRP), sICAM‐1, IL‐18, MCP‐1 and aldosterone, as well as the urinary concentrations of IL‐18, MCP‐1, aldosterone and 8‐hydroxy‐2′‐deoxyguanosine (8‐OHdG). Blood and urine samples were centrifuged immediately after collection, and the supernatants were stored at −80 and −30°C, respectively, until analysis. The concentrations of the pro‐inflammatory biomarkers were analyzed using samples obtained at baseline and at weeks 24 and 48. All samples were measured together once all specimens were collected.

An immunoturbidimetric assay was used for urinary albumin concentrations (Nitto Boseki Co. Ltd, Tokyo, Japan) and an immunonephelometric assay kit was used for hs‐CRP concentrations (Dade Behring, Marburg, Germany). Enzyme‐linked immunosorbent assay kits were used to measure IL‐18 (MBL, Nagoya, Japan), sICAM‐1 concentration and MCP‐1 concentrations (R&D Systems, Inc, Minneapolis, MN, USA), and 8‐OHdG concentration (Nikken SEIL Co. Ltd, Tokyo, Japan). A radioimmunoassay kit was used to measure aldosterone concentrations (TFB Co. Ltd, Tokyo, Japan). A1C was measured using a high‐pressure liquid chromatography method and is expressed in National Glycohemoglobin Standardization Program values. The urinary markers were divided by the urinary creatinine concentration to calculate the creatinine ratio for assessment.

Statistical Analysis {#jdi12004-sec-0010}
--------------------

Comparisons of baseline factors between the two therapeutic groups were analyzed by Student\'s unpaired *t*‐test for continuous parameters or chi‐squared‐test for categorical parameters (sex and previous therapy). Baseline concentrations of pro‐inflammatory markers, serum and urinary aldosterone concentrations, and urinary 8‐OHdG concentrations were compared using Student\'s unpaired *t*‐test. The percent change (% change) from baseline for pro‐inflammatory biomarkers, serum and urinary aldosterone concentrations, urinary 8‐OHdG concentration, A1C, BP,and C~Cr~ at 24 and 48 weeks was calculated and analyzed by analysis of variance ([anova]{.smallcaps}). The differences in the percent change of these parameters at each time between the two therapeutic groups were analyzed by [anova]{.smallcaps}. All analyses were two‐sided with a significance level of 5%. Data are expressed as the number for categorical variables, mean change from baseline for percent changes and mean ± standard deviation for continuous variables.

Results {#jdi12004-sec-0011}
=======

A total of 36 patients who met the inclusion criteria were screened (Figure [1](#jdi12004-fig-0001){ref-type="fig"}b). Before screening, all of the patients had received an ACEI and/or ARB. Four patients were excluded from the study during the washout period, including one patient who refused to participate in the study, two patients with an ACR \< 30 mg/gCr and one patient with C~Cr~ \< 60 mL/min. Therefore, 32 patients started the study. In two patients allocated to combination therapy, the doses of losartan and imidapril were 25 and 2.5 mg/day, respectively, for the first 4 weeks because their systolic BP (SBP) was \<120 mmHg. The doses in these patients were subsequently increased to 50 and 5 mg/day, respectively. During the observation period, two patients allocated to combination therapy were excluded from the study; one patient was hospitalized for hyperglycemia and one patient underwent surgery for colon carcinoma. In the monotherapy group, two patients were excluded during the observation period; one patient was hospitalized for pneumonia and one patient stopped visiting the hospital. Consequently, 14 patients in each therapeutic group, a total of 28 patients, completed 48 weeks of observation and were included in the analysis (Table [1](#jdi12004-tbl-0001){ref-type="table-wrap"}). There were no significant differences in baseline parameters between the two therapeutic groups, including age, sex, duration of diabetes, body mass index, A1C, Ccr, SBP, diastolic BP (DBP), ACR and previous therapy.

###### Baseline background of patients in each group

                                      Mono          Combination
  ----------------------------------- ------------- -------------
  No. patients                        14            14
  Age (years)                         61.4 ± 8.8    61.7 ± 5.3
  Sex (male/female)                   9/5           10/4
  Duration of diabetes (years)        11.7 ± 4.7    15.6 ± 6.7
  Body mass index (kg/m^2^)           25.4 ± 2.9    24.5 ± 5.1
  A1C (%)                             7.8 ± 1.5     7.8 ± 0.8
  Creatinine clearance (mL/min)       85.4 ± 16.1   90.1 ± 36.1
  Systolic blood pressure (mmHg)      136 ± 6       134 ± 12
  Diastolic blood pressure (mmHg)     79 ± 6        79 ± 7
  Albumin creatinine ratio (mg/gCr)   224 ± 197     270 ± 202
  Medication (*n*)                                  
  Insulin                             5             4
  Oral hyperglycemic agents           5             9
  Statins                             5             4

A1C, hemoglobin A1C; Mono, monotherapy.

Data are *n* or mean ± standard deviation.

John Wiley & Sons, Ltd

None of the patients developed new cerebrovascular disease, cardiovascular disease, arteriosclerosis obliterans, progression of nephropathy, excessive BP decrease or hyperkalemia during the study. Urinalysis showed no evidence of ketonuria, hematuria or urinary tract infection.

Time‐Course of A1C, BP and C~Cr~ {#jdi12004-sec-0012}
--------------------------------

There were no significant differences in percent change in A1C at 8, 16, 24 or 48 weeks between the monotherapy (7.8 ± 1.6, 8.0 ± 1.2, 8.0 ± 1.3 and 7.9 ± 1.2%, respectively) and combination therapy groups (7.8 ± 0.6, 8.1 ± 1.0, 8.1 ± 1.0 and 7.8 ± 0.8%, respectively). Similarly, there were no significant differences in SBP (monotherapy 137 ± 7, 136 ± 8, 135 ± 7 and 134 ± 8 mmHg; combination therapy 134 ± 12, 133 ± 10, 137 ± 10 and 134 ± 9 mmHg), DBP (monotherapy 80 ± 6, 79 ± 7, 81 ± 7 and 79 ± 5 mmHg; combination therapy 79 ± 8, 80 ± 8, 80 ± 8 and 78 ± 8 mmHg) or C~Cr~ (monotherapy 84.6 ± 18.6, 85.2 ± 20.4, 82.8 ± 18.6 and 84.6 ± 21.6 mL/min; combination therapy 85.2 ± 31.8, 87.6 ± 33.6, 86.4 ± 34.2 and 86.4 ± 30.6 mL/min) at 8, 16, 24 and 48 weeks of treatment.

Time‐Course of Serum Concentrations of Pro‐Inflammatory Biomarkers and Aldosterone {#jdi12004-sec-0013}
----------------------------------------------------------------------------------

At baseline, we found no significant differences in the serum concentrations of hs‐CRP, sICAM‐1, IL‐18, MCP‐1 or aldosterone between the two groups (Table [2](#jdi12004-tbl-0002){ref-type="table-wrap"}).

###### Change of the serum levels of inflammatory molecules and aldosterone

  Serum molecules        Week 0        Week 24                                         Week 48
  ---------------------- ------------- ----------------------------------------------- --------------------------------------------------------------------------------------
  hsCRP (mg/L)                                                                         
  All patients           1.33 ± 0.77   1.04 ± 0.79                                     0.71 ± 0.60
  \% change                            −13.7                                           −23.5[\*](#jdi12004-note-0003){ref-type="fn"}
  Mono                   1.39 ± 0.93   1.24 ± 1.01                                     1.04 ± 0.75
  \% change                            −0.4                                            −16.6
  Combination            1.26 ± 0.56   0.83 ± 0.39                                     0.78 ± 0.36
  \% change                            −28.0[\*](#jdi12004-note-0003){ref-type="fn"}   −31.0[‡](#jdi12004-note-0003){ref-type="fn"}
  sICAM‐1 (pg/mL)                                                                      
  All patients           275 ± 76      256 ± 74                                        250 ± 54
  \% change                            −5.9[\*](#jdi12004-note-0003){ref-type="fn"}    −6.4
  Mono                   282 ± 96      265 ± 100                                       262 ± 65
  \% change                            −5.4                                            −2.1
  Combination            269 ± 52      247 ± 35                                        238 ± 38
  \% change                            −6.4                                            −10.6[‡](#jdi12004-note-0003){ref-type="fn"}
  IL‐18 (pg/mL)                                                                        
  All patients           195 ± 62      209 ± 89                                        194 ± 75
  \% change                            +7.2                                            0.0
  Mono                   180 ± 49      214 ± 107                                       207 ± 73
  \% change                            +16.4                                           +11.6
  Combination            211 ± 72      204 ± 69                                        182 ± 53
  \% change                            −2.0                                            −11.4[\*](#jdi12004-note-0003){ref-type="fn"}[§](#jdi12004-note-0003){ref-type="fn"}
  MCP‐1 (pg/mL)                                                                        
  All patients           308 ± 95      283 ± 78                                        282 ± 63
  \% change                            −6.3[\*](#jdi12004-note-0003){ref-type="fn"}    −5.6[\*](#jdi12004-note-0003){ref-type="fn"}
  Mono                   331 ± 114     295 ± 84                                        291 ± 71
  \% change                            −7.8                                            −8.0
  Combination            285 ± 68      270 ± 74                                        273 ± 56
  \% change                            −4.8                                            −3.2
  Aldosterone (pmol/L)                                                                 
  All patients           2470 ± 1180   2230 ± 930                                      1760 ± 950
  \% change                            −5.4                                            −27.0[‡](#jdi12004-note-0003){ref-type="fn"}
  Mono                   2680 ± 1220   2510 ± 840                                      1860 ± 1210
  \% change                            +1.4                                            −31.2[‡](#jdi12004-note-0003){ref-type="fn"}
  Combination            2260 ± 1150   1960 ± 960                                      1650 ± 610
  \% change                            −12.1[\*](#jdi12004-note-0003){ref-type="fn"}   −22.7[†](#jdi12004-note-0003){ref-type="fn"}

Data are means ± SD or frequencies (%).\**P *\< 0.05, †*P *\< 0.01, ‡*P *\< 0.005 versus baseline. ^§^*P *\< 0.05 for combination versus monotherapy (Mono).

John Wiley & Sons, Ltd

In all patients, the serum hs‐CRP concentration decreased significantly from baseline by 23.5% at 48 weeks. In the combination therapy group, the serum hs‐CRP concentration decreased significantly from baseline by 28.0 and 31.0% at 24 and 48 weeks, respectively. The serum hs‐CRP concentration decreased by 16.6% at 48 weeks in the monotherapy group, although not significantly (Table [2](#jdi12004-tbl-0002){ref-type="table-wrap"}). The serum sICAM‐1 concentration decreased significantly by 10.6% at 48 weeks in the combination therapy group, but did not change significantly in the monotherapy group (Table [2](#jdi12004-tbl-0002){ref-type="table-wrap"}). The serum IL‐18 concentration decreased significantly by 11.4% at 48 weeks in the combination therapy group, but tended to increase in the monotherapy group, resulting in a significant difference in the percent change between the two groups at 48 weeks (Table [2](#jdi12004-tbl-0002){ref-type="table-wrap"}). In all patients, the serum MCP‐1 concentration decreased significantly from baseline by 6.3 and 5.6% at 24 and 48 weeks, respectively. The serum MCP‐1 concentration decreased in both therapeutic groups, although the percent change was not significant. The serum aldosterone concentration decreased significantly from baseline at 48 weeks in all patients and in both groups (Table [2](#jdi12004-tbl-0002){ref-type="table-wrap"}).

Time‐Course of ACR and Urinary Concentrations of IL‐18, MCP‐1, Aldosterone and 8‐OHdG {#jdi12004-sec-0014}
-------------------------------------------------------------------------------------

At baseline, there were no significant differences between the two groups in ACR or urinary concentrations of IL‐18, MCP‐1, aldosterone or 8‐OHdG (Table [3](#jdi12004-tbl-0003){ref-type="table-wrap"}).

###### Change of the urinary levels of albumin/creatinine ratio, inflammatory molecules, aldosterone and 8‐hydroxy‐2′‐deoxyguanosine

  Urinary molecules         Week 0        Week 24                                                                               Week 48
  ------------------------- ------------- ------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  ACR (mg/gCr)                                                                                                                  
  All patients              252 ± 197     200 ± 202                                                                             175 ± 159
  \% change                               −8.3[‡](#jdi12004-note-0004){ref-type="fn"}                                           −11.0[‡](#jdi12004-note-0004){ref-type="fn"}
  Mono                      234 ± 197     209 ± 221                                                                             182 ± 128
  \% change                               −3.5                                                                                  −6.2[\*](#jdi12004-note-0004){ref-type="fn"}
  Combination               270 ± 202     192 ± 189                                                                             168 ± 191
  \% change                               −12.8[‡](#jdi12004-note-0004){ref-type="fn"}[§](#jdi12004-note-0004){ref-type="fn"}   −15.4[‡](#jdi12004-note-0004){ref-type="fn"}[§](#jdi12004-note-0004){ref-type="fn"}
  IL‐18 (pg/mL/Cr)                                                                                                              
  All patients              57 ± 62       33 ± 34                                                                               13 ± 14
  \% change                               −15.7                                                                                 −24.3
  Mono                      39 ± 35       25 ± 17                                                                               19 ± 17
  \% change                               −7.3                                                                                  +6.8
  Combination               75 ± 77       40 ± 45                                                                               8 ± 8
  \% change                               −24.1                                                                                 −55.3[‡](#jdi12004-note-0004){ref-type="fn"}[§](#jdi12004-note-0004){ref-type="fn"}
  MCP‐1 (pg/mL/Cr)                                                                                                              
  All patients              318 ± 192     205 ± 101                                                                             340 ± 244
  \% change                               −15.4                                                                                 +22.4[\*](#jdi12004-note-0004){ref-type="fn"}
  Mono                      341 ± 220     216 ± 109                                                                             351 ± 216
  \% change                               −15.4                                                                                 +32.8
  Combination               294 ± 164     195 ± 95                                                                              329 ± 277
  \% change                               −15.4                                                                                 +12.0
  Aldosterone (pmol/L/Cr)                                                                                                       
  All patients              100 ± 70      48 ± 45                                                                               68 ± 54
  \% change                               −50.9[‡](#jdi12004-note-0004){ref-type="fn"}                                          −29.1[‡](#jdi12004-note-0004){ref-type="fn"}
  Mono                      125 ± 79      68 ± 52                                                                               89 ± 59
  \% change                               −35.7[\*](#jdi12004-note-0004){ref-type="fn"}                                         −22.6[\*](#jdi12004-note-0004){ref-type="fn"}
  Combination               77 ± 68       29 ± 28                                                                               47 ± 41
  \% change                               −65.1[‡](#jdi12004-note-0004){ref-type="fn"}                                          −35.2
  8‐OHdG (pg/mL/Cr)                                                                                                             
  All patients              12.8 ± 5.0    8.2 ± 4.2                                                                             8.6 ± 3.4
  \% change                               −28.6[‡](#jdi12004-note-0004){ref-type="fn"}                                          −26.6[‡](#jdi12004-note-0004){ref-type="fn"}
  Mono                      13.7 ± 3.8    9.7 ± 4.3                                                                             10.7 ± 3.1
  \% change                               −23.8[\*](#jdi12004-note-0004){ref-type="fn"}                                         −15.4[‡](#jdi12004-note-0004){ref-type="fn"}
  Combination               12.0  ± 5.9   6.8 ± 3.6                                                                             6.5 ± 2.3
  \% change                               −33.5[†](#jdi12004-note-0004){ref-type="fn"}                                          −37.8[‡](#jdi12004-note-0004){ref-type="fn"}[§](#jdi12004-note-0004){ref-type="fn"}

Data are means ± SD or frequencies (%). \**P *\< 0.05, †*P *\<* *0.01, ‡*P *\<* *0.005 versus baseline. §*P *\<* *0.05 for combination versus monotherapy (Mono).

John Wiley & Sons, Ltd

In all patients, ACR decreased significantly by 8.3 and 11.0% at 24 and 48 weeks, respectively. ACR decreased significantly by 6.2% at 48 weeks in the monotherapy group and by 12.8 and 15.4% at 24 and 48 weeks, respectively, in the combination therapy group. The percent change (decrease) in ACR was significantly greater in the combination therapy group than in the monotherapy group at both times (Table [3](#jdi12004-tbl-0003){ref-type="table-wrap"}). In all patients, the urinary IL‐18 concentration tended to decrease over time, although not significantly. In the combination therapy group, the urinary IL‐18 concentration decreased significantly by 55.3% at 48 weeks, and the percent change was significantly different from that in the monotherapy group (Table [3](#jdi12004-tbl-0003){ref-type="table-wrap"}). In all patients, the urinary MCP‐1 concentration decreased by 15.4% at 24 weeks, but increased significantly by 22.4% at 48 weeks. In both groups, the urinary MCP‐1 concentration was increased at 48 weeks. The urinary aldosterone concentration was significantly decreased at all times in all patients and in both treatment groups; however, there were no significant differences in the percent changes between the two groups (Table [3](#jdi12004-tbl-0003){ref-type="table-wrap"}). In all patients, the urinary 8‐OHdG concentration decreased significantly from baseline by 28.6 and 26.6% at 24 and 48 weeks, respectively. The urinary 8‐OHdG concentration decreased significantly by 23.8% at 24 weeks in the monotherapy group and by 33.5 and 37.8% at 24 and 48 weeks, respectively, in the combination therapy group. The percent change in 8‐OHdG concentration at 48 weeks was significantly greater in the combination therapy group than in the monotherapy group (Table [3](#jdi12004-tbl-0003){ref-type="table-wrap"}).

Discussion {#jdi12004-sec-0015}
==========

The present study showed that treatment with losartan and imidapril was more effective than treatment with amlodipine in decreasing ACR as well as inflammatory and oxidative stress markers in serum and urine in Japanese patients with type 2 diabetes and nephropathy. These effects were maintained for 48 week. Combination therapy with losartan and imidapril was more useful in decreasing ACR, and pro‐inflammatory and oxidative stress markers than losartan administered at a double dose, without differences in BP or glycemic control. These results suggest that the losartan/imidapril combination might be useful to prevent the progression of atherosclerosis and nephropathy in patients with type 2 diabetes by exerting anti‐inflammatory and anti‐oxidative effects through inhibition of the RAS.

The RAS and downstream inflammatory activities are involved in the progression of atherosclerosis[16](#jdi12004-bib-0016){ref-type="ref"}. In the present study, treatment with losartan and imidapril did not significantly change A1C or BP, but hs‐CRP levels at 24 and 48 weeks, and sICAM‐1 levels at 48 weeks were significantly lower than those at baseline; these changes were not observed in the monotherapy group. Amlodipine was reported to have anti‐inflammatory and anti‐oxidative stress effects, and to inhibit the production of hs‐CRP and sICAM‐1[17](#jdi12004-bib-0017 jdi12004-bib-0018){ref-type="ref"}. RAS inhibitors also have anti‐inflammatory effects, which are favorable cardiovascular effects, independent of their antihypertensive effects[19](#jdi12004-bib-0019 jdi12004-bib-0020){ref-type="ref"}. The present study showed that losartan and imidapril could inhibit the progression of atherosclerosis by their anti‐inflammatory effects through inhibition of the RAS more potently than amlodipine.

The serum IL‐18 concentration tended to be increased in the monotherapy group, but decreased significantly in the combination therapy group, resulting in a significant difference between the two groups at 48 weeks. Serum IL‐18 is an important prognostic predictor of diabetic nephropathy and atherosclerosis[21](#jdi12004-bib-0021){ref-type="ref"}. It has been reported that ARBs and ACEIs decrease IL‐18 by inhibiting the RAS[22](#jdi12004-bib-0022){ref-type="ref"}. In the present study, amlodipine was only administered during the washout period. Therefore, the efficacy of losartan and imidapril represented the change from treatment with amlodipine. Based on our searches of the literature, amlodipine has no known effect on serum IL‐18 concentrations. These results indicate that imidapril/losartan combination therapy could have better anti‐inflammatory efficacy in patients with type 2 diabetes with nephropathy, as compared with amlodipine or losartan monotherapy.

Similar to microinflammation, oxidative stress is profoundly involved in the development of atherosclerosis and diabetic complications[23](#jdi12004-bib-0023){ref-type="ref"}. 8‐OHdG is a biomarker of systemic DNA damage in diabetic nephropathy[24](#jdi12004-bib-0024){ref-type="ref"}. In the present study, the urinary 8‐OHdG concentration decreased significantly after treatment with losartan and imidapril, as compared with baseline levels. The decrease in urinary 8‐OHdG concentrations was greater in the combination therapy group than in the monotherapy group. It has been reported that amlodipine[17](#jdi12004-bib-0017 jdi12004-bib-0018){ref-type="ref"}, ACEI[11](#jdi12004-bib-0011){ref-type="ref"} and ARB[12](#jdi12004-bib-0012 jdi12004-bib-0019){ref-type="ref"} suppress oxidative stress. However, it is unclear which of these agents or which combination of these drugs elicits the greatest reduction in oxidative stress in patients with diabetic nephropathy. The present results suggest that imidapril/losartan combination therapy might be more effective in preventing the development or progression of diabetic nephropathy because of its more potent inhibitory effects on oxidative stress than losartan monotherapy. These effects were maintained for up to 48 weeks.

The urinary aldosterone concentration was also decreased more markedly by combination therapy than monotherapy in the present study, which suggests that combination therapy more potently inhibits the RAS in the kidney. The urinary IL‐18 concentration was also significantly decreased by combination therapy as compared with monotherapy. We previously reported that serum and urine IL‐18 concentrations are predictors of diabetic nephropathy[21](#jdi12004-bib-0021){ref-type="ref"}. IL‐18 secretion in monocytes and macrophages is stimulated by inflammation and oxidative stress associated with hyperglycemia[25](#jdi12004-bib-0025){ref-type="ref"}. These results suggest that the combination of losartan and imidapril might be useful to prevent the development of early nephropathy in patients with type 2 diabetes by decreasing ACR, and reducing inflammation and oxidative stress in the kidney through more potent inhibition of the RAS.

The main limitation of the present study was that the observation period was not long enough to evaluate renal or cardiovascular outcomes. The Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT)[26](#jdi12004-bib-0026){ref-type="ref"}, and Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial (ONTARGET)[27](#jdi12004-bib-0027){ref-type="ref"} studies both showed that combination therapy with an ACEI and an ARB did not have significant benefits on renal outcomes. However, in the ORIENT study[26](#jdi12004-bib-0026){ref-type="ref"}, combination therapy with olmesartan and an ACEI reduced proteinuria, as observed in the present study, but did not further improve renal or cardiovascular outcomes. The reason for these discrepancies remains unclear. Further studies are required to confirm the beneficial effect of combination therapy with an ARB and an ACEI on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

In the present study, the sample size of 28 patients was small, meaning larger studies are required to confirm these results. Although the serum and urinary concentrations of several biomarkers decreased after monotherapy or combination therapy, some changes were not statistically significant, perhaps because of the small sample size. Although amlodipine was used during the washout period to prevent possible changes in BP, we measured ambulatory BP at a single time, so we cannot exclude the possible effects of BP on the decrease in ACR. A larger clinical study using 24‐h BP monitoring might be required to verify the results of the present study.

In conclusion, a combination of an ACEI and an ARB could be beneficial for treating diabetic nephropathy through their anti‐inflammatory and anti‐oxidative stress effects.

This study was supported in part by a Grant‐in‐Aid for Scientific Research (C) to K Shikata (21591031), a Grant‐in‐Aid for Young Scientists (B) to D Ogawa (23790942) from the Ministry of Education, Culture, Sports, Science and Technology, and by a Grant‐in‐Aid for Diabetic Nephropathy Research from the Ministry of Health, Labour and Welfare of Japan. This work was also supported by the Takeda Science Foundation, the Naito Foundation, the Japan Foundation for Applied Enzymology, and the Ryobi Teien Memory Foundation. We thank the staff at Okayama Saiseikai General Hospital for their cooperation in this study. The authors have no potential conflicts of interest relevant to this study to report.
